Abstract:
Background: Breast cancer is a leading cause of morbidity and deaths among women worldwide. In Tanzania there is no published data on human epidermal growth receptor-2 (HER2/neu) expression in breast carcinoma. Hormonal receptors and HER2/neu status reportedly influence post-mastectomy adjuvant therapy and predict
treatment outcome and prognosis. Here we evaluate hormonal receptors and HER-2 status in biopsies of women with breast cancer at Muhimbili National Hospital (MNH).
Methods: A cross-sectional study of female breast post-modified radical mastectomy (MRM)/incisional biopsies confirmed to be carcinoma at the Histopathology Unit (January–December 2013). Tissue blocks having poor morphology, without tumor, secondary tumors, cases outside the study period and male patients were excluded.
Routine staining was done followed by immunohistochemistry for estrogen (ER), and progesterone (PgR) receptors and HER2. Data analyzed using Statistical Package for Social Sciences (SPSS).
Results: A total of 218 cases were confirmed to be carcinoma including 70 meeting inclusion criteria. Age at
diagnosis ranged 18–75 years and mean age was 48.36 years. Majority (64.3%) were in the 36–55 years age-group.
Histologically, most (88.6%) women had invasive ductal carcinoma including 43.1% of intermediate grade. A great
majority (78%) were stage three. Due to logistical constrains, 75.7% (n = 53/70) cases where immunostained for
hormones including 43.4% (ER+), 26.4% (PgR+), and 28% (ER+/PgR+). Furthermore, 65.7% (n = 46/70) cases were
immunostained for HER-2 and 15.2% (n = 7/46) were positive, 45.6% were triple negative (ER-,PgR-,HER2-), 23.9% (ER
+,PgR+,HER2-) or luminal B, 2.2% (ER+,PgR-,HER2+),13% (ER-,PgR-,HER2+) and 15% (ER+,PgR-,HER2-) with none being
triple positive.
Conclusions: Hormonal receptors and HER2 expression at MNH appears to be comparable to previous Africans/
African Americans report but not with studies among Caucasians and the current proportion of triple-negative breast carcinomas (TNBC) is higher than in a previous Tanzanian report and a majority are luminal. HER2 over- the expression is relatively common. It is strongly recommended that receptor status assessment be made routine for breast cancer patients at MNH.
